The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer

Sangeeta Rojanala, Haiyong Han, Rubén M. Muñoz, Walden Browne, Raymond B Nagle, Daniel D. Von Hoff, David J. Bearss

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Aurora-2 is a serine threonine kinase that associates with the centrosome. Overexpression or ectopic expression of Aurora-2 appears to alter centrosome number and function and has been implicated in a variety of human cancers. In this work, we demonstrate that Aurora-2 is both amplified and overexpressed in human pancreatic cancer cell lines, with a 2-5-fold increase in gene copy number and a 3-4-fold increase in protein levels compared with controls. Aurora-2 is also amplified and overexpressed in pancreatic cancers taken directly from patients. An immunohistochemistry of tissues taken directly from patients demonstrated an overexpression of Aurora-2 in 26 of 28 pancreatic cancers compared with 18 normal pancreas samples. Antisense nucleotides specifically targeted at Aurora-2 arrest the cell cycle in pancreatic cancer cells, indicating the potential of Aurora-2 as a therapeutic target in pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)451-457
Number of pages7
JournalMolecular Cancer Therapeutics
Volume3
Issue number4
StatePublished - Apr 2004

Fingerprint

Protein-Serine-Threonine Kinases
Human Development
Pancreatic Neoplasms
Centrosome
Pharmaceutical Preparations
Gene Dosage
Cell Cycle Checkpoints
Pancreas
Nucleotides
Immunohistochemistry
Cell Line
Neoplasms
Proteins

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Pharmacology

Cite this

Rojanala, S., Han, H., Muñoz, R. M., Browne, W., Nagle, R. B., Von Hoff, D. D., & Bearss, D. J. (2004). The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer. Molecular Cancer Therapeutics, 3(4), 451-457.

The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer. / Rojanala, Sangeeta; Han, Haiyong; Muñoz, Rubén M.; Browne, Walden; Nagle, Raymond B; Von Hoff, Daniel D.; Bearss, David J.

In: Molecular Cancer Therapeutics, Vol. 3, No. 4, 04.2004, p. 451-457.

Research output: Contribution to journalArticle

Rojanala, S, Han, H, Muñoz, RM, Browne, W, Nagle, RB, Von Hoff, DD & Bearss, DJ 2004, 'The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer', Molecular Cancer Therapeutics, vol. 3, no. 4, pp. 451-457.
Rojanala, Sangeeta ; Han, Haiyong ; Muñoz, Rubén M. ; Browne, Walden ; Nagle, Raymond B ; Von Hoff, Daniel D. ; Bearss, David J. / The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer. In: Molecular Cancer Therapeutics. 2004 ; Vol. 3, No. 4. pp. 451-457.
@article{de265cab007c4ffaaf76bd440e5203f8,
title = "The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer",
abstract = "Aurora-2 is a serine threonine kinase that associates with the centrosome. Overexpression or ectopic expression of Aurora-2 appears to alter centrosome number and function and has been implicated in a variety of human cancers. In this work, we demonstrate that Aurora-2 is both amplified and overexpressed in human pancreatic cancer cell lines, with a 2-5-fold increase in gene copy number and a 3-4-fold increase in protein levels compared with controls. Aurora-2 is also amplified and overexpressed in pancreatic cancers taken directly from patients. An immunohistochemistry of tissues taken directly from patients demonstrated an overexpression of Aurora-2 in 26 of 28 pancreatic cancers compared with 18 normal pancreas samples. Antisense nucleotides specifically targeted at Aurora-2 arrest the cell cycle in pancreatic cancer cells, indicating the potential of Aurora-2 as a therapeutic target in pancreatic cancer.",
author = "Sangeeta Rojanala and Haiyong Han and Mu{\~n}oz, {Rub{\'e}n M.} and Walden Browne and Nagle, {Raymond B} and {Von Hoff}, {Daniel D.} and Bearss, {David J.}",
year = "2004",
month = "4",
language = "English (US)",
volume = "3",
pages = "451--457",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer

AU - Rojanala, Sangeeta

AU - Han, Haiyong

AU - Muñoz, Rubén M.

AU - Browne, Walden

AU - Nagle, Raymond B

AU - Von Hoff, Daniel D.

AU - Bearss, David J.

PY - 2004/4

Y1 - 2004/4

N2 - Aurora-2 is a serine threonine kinase that associates with the centrosome. Overexpression or ectopic expression of Aurora-2 appears to alter centrosome number and function and has been implicated in a variety of human cancers. In this work, we demonstrate that Aurora-2 is both amplified and overexpressed in human pancreatic cancer cell lines, with a 2-5-fold increase in gene copy number and a 3-4-fold increase in protein levels compared with controls. Aurora-2 is also amplified and overexpressed in pancreatic cancers taken directly from patients. An immunohistochemistry of tissues taken directly from patients demonstrated an overexpression of Aurora-2 in 26 of 28 pancreatic cancers compared with 18 normal pancreas samples. Antisense nucleotides specifically targeted at Aurora-2 arrest the cell cycle in pancreatic cancer cells, indicating the potential of Aurora-2 as a therapeutic target in pancreatic cancer.

AB - Aurora-2 is a serine threonine kinase that associates with the centrosome. Overexpression or ectopic expression of Aurora-2 appears to alter centrosome number and function and has been implicated in a variety of human cancers. In this work, we demonstrate that Aurora-2 is both amplified and overexpressed in human pancreatic cancer cell lines, with a 2-5-fold increase in gene copy number and a 3-4-fold increase in protein levels compared with controls. Aurora-2 is also amplified and overexpressed in pancreatic cancers taken directly from patients. An immunohistochemistry of tissues taken directly from patients demonstrated an overexpression of Aurora-2 in 26 of 28 pancreatic cancers compared with 18 normal pancreas samples. Antisense nucleotides specifically targeted at Aurora-2 arrest the cell cycle in pancreatic cancer cells, indicating the potential of Aurora-2 as a therapeutic target in pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=4444239881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444239881&partnerID=8YFLogxK

M3 - Article

C2 - 15078988

AN - SCOPUS:4444239881

VL - 3

SP - 451

EP - 457

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 4

ER -